文献速递外周动脉疾病

药物涂层球囊与镍钛裸金属支架治疗股腘动脉原发病变的中期疗效与安全性比较

Mid-term Efficacy and Safety of Drug-coated Balloon versus Nitinol Bare Metal Stent for Primary Lesions in Femoropopliteal Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2021-11-09

单中心纳入284例324条肢体的股腘动脉原发病变,比较药物涂层球囊与裸金属支架,随访24个月。两组一期通畅率、免于临床驱动靶肢体血运重建率、总生存率及复合安全终点均无显著差异,亚组分析亦无显著差异。

要点

  • 24个月一期通畅率裸金属支架组63.9% vs 药物涂层球囊组70.2%,无显著差异(log-rank P=0.167)。
  • 24个月免于临床驱动靶肢体血运重建率裸金属支架组82.5% vs 药物涂层球囊组85.9%,无显著差异(log-rank P=0.342)。
  • 24个月总生存率与免于复合安全终点两组无显著差异。

核心结论

  • 随访24个月,裸金属支架与药物涂层球囊治疗股腘动脉原发病变的疗效和安全性结局相当,提示可能减少永久性金属植入物的置入。

研究设计与样本

  • 单中心纳入接受裸金属支架或药物涂层球囊治疗的股腘动脉原发病变患者,随访24个月,共284例患者324条肢体。
  • 采用血管外科学会推荐的标淮报告临床和解剖状态,主要终点包括24个月一期通畅率、临床驱动靶肢体血运重建、复合安全终点和全因死亡,采用Kaplan-Meier评估。

主要发现

  • 12个月一期通畅率裸金属支架组75.3% vs 药物涂层球囊组80.9%,24个月降至裸金属支架组63.9% vs 药物涂层球囊组70.2%(log-rank P=0.167)。
  • 12个月免于临床驱动靶肢体血运重建率裸金属支架组86.8% vs 药物涂层球囊组92.7%,24个月降至裸金属支架组82.5% vs 药物涂层球囊组85.9%(log-rank P=0.342)。
  • 24个月时,流出道差病变一期通畅率裸金属支架组58.8% vs 药物涂层球囊组67.3%(log-rank P=0.127),严重钙化病变64.5% vs 69.4%(log-rank P=0.525),腘动脉受累病变59.3% vs 60.3%(log-rank P=0.695),均无显著差异。
  • 24个月总生存率裸金属支架组92.6% vs 药物涂层球囊组90.3%(log-rank P=0.391),免于复合安全终点79.3% vs 79.2%(log-rank P=0.941),均无显著差异。

关键数值与推荐

  • 裸金属支架组74例、药物涂层球囊组71例为间歇性跛行,裸金属支架组83例、药物涂层球囊组56例为慢性肢体威胁性缺血。
  • 平均累积病变长度裸金属支架组18.7±9.8cm,药物涂层球囊组17.2±10.3cm。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare drug-coated balloon (DCB) and bare metal stent (BMS) for primary lesions in femoropopliteal artery disease in Chinese population and to make subgroup analysis between the groups. METHODS: Patients with primary lesions who underwent BMS or DCB treatment of a single tertiary vascular center were included and followed up for 24 months. Clinical and anatomic status were reported using the criteria recommended by the Society for Vascular Surgery. The primary endpoint included primary patency, clinically target limb revascularization, composite safety endpoint and all-cause death over 24 months assessed by Kaplan-Meier. Secondary endpoints included technical success rate and stent-related complications. RESULTS: A total of 284 patients with 324 limbs were pooled into analysis and most of the baseline characteristics did not show significant difference. A total of 74 in BMS group and 71 in DCB group were claudicants while 83 in BMS group and 56 in DCB group suffered from chronic limb threatening ischemia (CLTI). The mean cumulative lesion length was 18.7 ± 9.8cm in BMS group while 17.2 ± 10.3cm in DCB group. Kaplan-Meier estimates of primary patency were 75.3% and 80.9% for BMS and DCB groups at 12 months while decreased to 63.9% and 70.2% at 24 months (log-rank P = 0.167), respectively. Freedom from clinically driven target limb revascularization was 86.8% and 92.7% for BMS and DCB groups at 12 months while dropped to 82.5% and 85.9% at 24 months (log-rank P = 0.342). Estimates of primary patency between BMS and DCB group did not show significant difference on lesions with poor runoff (58.8% vs. 67.3%, log-rank P = 0.127), severe calcification (64.5% vs. 69.4%, log-rank P = 0.525) and popliteal artery involvement (59.3% vs. 60.3%, log-rank P = 0.695) at 24 months. The overall survival (92.6% for BMS, 90.3% for DCB, log-rank P = 0.391) and freedom from composite safety endpoint (79.3% for BMS, 79.2% for DCB, log-rank P = 0.941) showed no significant difference at 24 months. CONCLUSIONS: Over the 24 month follow-up, BMS and DCB showed equivalent efficacy and safety outcomes for primary femoropopliteal artery disease, which indicated the reduction of permanent metallic implant insertion might be possible.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ma H, Zhang X, Li J, et al. Mid-term Efficacy and Safety of Drug-coated Balloon versus Nitinol Bare Metal Stent for Primary Lesions in Femoropopliteal Artery Disease. Ann Vasc Surg. 2021. PMID: 34762999. doi:10.1016/j.avsg.2021.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。